Vol. 31.Issue. 1. January - June 2026 | Annals of Hepatology

Tienda Elsevier

¿Aún no está registrado?

Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta

* = Required fields

Enter your email address

User name *

Annals of Hepatology

Annals of Hepatology

Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

4.4

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2024

9.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2024

1.011

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2024

1.057

View more metrics

Journal Information

Previous Issue | Next Issue

Issue

portada-S1665268125X00041

Vol. 31. Issue 1. (In progress)

(January - June 2026)

This issue is in progress but contains articles that are final and fully citable.

Opinions

Beyond the association: towards an integrated hepato–renal approach

Juanita Pérez-Escobar, Ricardo Ivan Velazquez-Silva, Paulina Carpinteyro-Espin, José Carlos Gasca-Aldama

Ann Hepatol. 2026;31:102155

Full text access

Share

Original articles

Impact of neohepatic albumin-bilirubin scores on renal outcomes following living donor liver transplantation: a propensity score analysis

Hye-Won Jeong, Hye-Mee Kwon, Sung-Hoon Kim, Seong-Mi Yang, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang

Ann Hepatol. 2026;31:102111

Full text access

Share

Prognosis of hepatocellular carcinoma in the French overseas territories and comparison with a tertiary center in mainland France

Alolia Aboikoni, Manon Allaire, Dominique Louvel, Marthe Alogo A. Nwatsok, Paul Ngock Dime, Ala Ouni, Larissa Tangan, Magaly Zappa, ... Moana Gelu-Simeon

Ann Hepatol. 2026;31:102120

Full text access

Share

Diagnosis of metabolic dysfunction-associated steatotic liver disease by triglyceride glucose-body mass index: A systematic review and meta-analysis

Kexin Du, Yafang Huang, Yanhui Yu, Jianrong Guo, Jianmei Feng, Feng Jiang

Ann Hepatol. 2026;31:102122

Full text access

Share

Epidemiology and etiologic trends of hepatocellular carcinoma in cirrhotic patients in Mexico: a multicenter retrospective study (2018–2024)

Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Carlos Cortez-Hernández, Elianee M. Tovar-Bojorquez, Raúl Contreras-Omaña, Juan D. Monsiváis-Morales, Jacqueline Cordova-Gallardo, Mauricio Castillo-Barradas, ... Heriberto Rodríguez-Hernández

Ann Hepatol. 2026;31:102131

Full text access

Share

Bidirectional association between chronic liver disease and chronic kidney disease: a longitudinal study based on CHARLS 2011–2020 data

Yuan He, Fan Zhang, Zixuan Zhang, Xianwen Zhang, Yifei Zhong

Ann Hepatol. 2026;31:102115

Full text access

Share

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab

Lorenz Kocheise, Jan Kempski, Yunhe Tang, Lorenz Balcar, Victoria Berger, Miriam Tomczak, Joao Gorgulho, Ramsha Masood, ... Kornelius Schulze

Ann Hepatol. 2026;31:102138

Full text access

Share

Antibiotic consumption, genetic risk and incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

Ziming Zheng, Yumei Huang, Jijuan Zhang, Jinchi Xie, An Pan, Yunfei Liao, Yu Zhang

Ann Hepatol. 2026;31:102136

Full text access

Share

Comparisons of global incidence and risk factor profiles of hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Tianhao Wu, Mingyi Du, Tiejun Zhang, Xingdong Chen, Zhenqiu Liu

Ann Hepatol. 2026;31:102139

Full text access

Share

Trends and health inequalities of hepatitis virus-associated liver cancer mortality during 1990–2050

Yujiao Deng, Jingyue Tan, Jian Zu, Zixuan Xing, Zhanpeng Yang, Yue Zhang, Yajing Bo, Xu Gao, ... Yang Yang

Ann Hepatol. 2026;31:102144

Full text access

Share

Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis

Xiaohui Ye, Lingling He, Caihong Deng, Junru Yang, Ping Li, Hongshan Wei

Ann Hepatol. 2026;31:102150

Full text access

Share

Piloting eLearning initiatives: Computer-based training and telementoring for viral hepatitis care in public primary care setting

Janus P. Ong, Geohari Hamoy, Eric David B. Ornos, Vanessa Co-Tanco, Joy Gillera, Jhunnel Macalanda, Jae-Ann Sumalo

Ann Hepatol. 2026;31:102133

Full text access

Share

Aspartate aminotransferase‑to‑platelet ratio index (APRI) reliably excludes advanced fibrosis and cirrhosis in treated autoimmune hepatitis

Martine A.M.C. Baven-Pronk, Camiel J.M. Marijnissen, Maaike Biewenga, Albert F. Stättermayer, Maarten E. Tushuizen, Bart van Hoek

Ann Hepatol. 2026;31:102146

Full text access

Share

Incidence and predictors of non-hepatic cancers in biopsy-proven alcohol-related liver disease

Mayur Brahmania, Zaid Hindi, Nancy Shi, Juan Pablo Arab, Neil Rajoriya, Guruprasad P. Aithal, Michael Allison, Hannes Hagström, ... WALDO investigators

Ann Hepatol. 2026;31:101908

Full text access

Share

Long-term albumin treatment for decompensated cirrhosis in Italy: A propensity score-matched, retrospective, real-world chart analysis

Wim Laleman, Jonel Trebicka, Alastair O’Brien, Giacomo Zaccherini, Paolo Caraceni, Joana F. Rodrigues, Xiang Zhang, Maebh Kelly, ... Paolo Angeli

Ann Hepatol. 2026;31:102153

Full text access

Share

Effects of artificial liver support systems on nosocomial infections and mortality in non-transplanted liver failure patients

Yuan Li, Xiaoting Wang, Junkai Fan, Jiale Xie, Huimin Liu, Chunrong Ping, Zhijie Feng, Yan Wang

Ann Hepatol. 2026;31:102113

Full text access

Share

Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH

Bradley Jermy, Jack Brownrigg, Pavel Strnad, Rohit Loomba

Ann Hepatol. 2026;31:102143

Full text access

Share

A multinational survey of physician knowledge about management of chronic hepatitis C

Mohamed El-Kassas, Yusuf Yilmaz, Chun-Jen Liu, Marlen I.Castellanos Fernández, Yuichiro Eguchi, Khalid Al-Naamani, Doaa Abdeltawab, Mohammed A. Medhat, ... the Global Liver Council

Ann Hepatol. 2026;31:102134

Full text access

Share

Simultaneous physical and nutritional intervention reduces frailty in patients with cirrhosis listed for liver transplantation: a randomized controlled trial

Carlos Benítez, Diego Reyes, Catalina Grandy, Isidora Thomas, Nicolás Lavados, Nicole Kim, Anny Gálvez, Silvana Valdés, ... Roberto Candia

Ann Hepatol. 2026;31:102114

Full text access

Share

Reevaluating the clinical course of AMA-positive patients with normal liver enzymes: A large retrospective cohort study

Ahmad Yahia, Fadi Abu Baker, Mifleh Tatour, Rawi Hazzan

Ann Hepatol. 2026;31:102147

Full text access

Share

Real-world BCLC adherence and survival in hepatocellular carcinoma: first prospective study from Central America

Pablo Coste Murillo, María Fernanda Lynch-Mejía, Wagner Ramírez Quesada, Francisco Vargas Navarro, Vanessa López Jara, Silvia Alfaro Cartín, Ariela Gómez Pérez, Sheila Araya Chavarría, ... Karen Melissa Rodríguez Masís

Ann Hepatol. 2026;31:102154

Full text access

Share

Assessment of metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, and metabolic dysfunction and alcohol-associated steatotic liver disease in open Mexican population

Jorge Emilio Lira-Vera, Ángel Daniel Santana-Vargas, Gabriela Gutiérrez-Reyes, Oscar Morales-Gutiérrez, María de Fátima Higuera-de la Tijera, Diana Montemira-Orozco, Christian Hinojosa-Segura, Moisés Martínez-Castillo, ... José Luis Pérez-Hernández

Ann Hepatol. 2026;31:102149

Full text access

Share

Different measures of sodium intake and the risk of metabolic dysfunction-associated steatotic liver disease: Evidence from the UK Biobank

Shiqi Zhu, Lihe Liu, Yiping Shen, Rui Li, Jiaxi Lin, Lu Liu, Xiaolin Liu, Hongpeng Sun, Jinzhou Zhu

Ann Hepatol. 2026;31:102145

Full text access

Share

Natural history and outcomes of MASLD and MetALD following non-alcoholic fatty liver disease reclassification in a Canadian cohort

Yousef Almahanna, Francisco Idalsoaga, Luis Antonio Díaz, Ahmed Almohsen, Yi Nong Song, Amani Bajunayd, Rokhsana Mortuza, Jeemin Kim, ... Juan Pablo Arab

Ann Hepatol. 2026;31:102166

Full text access

Share

Early-life exposure to tobacco smoke and chronic liver disease incidence in adulthood

Xiaoqin Xu, Jiang Li, Yanqi Fu, Jie Li, Wenqi Shen, Xiao Tan, Jinyi Wu, Ningjian Wang, ... Bin Wang

Ann Hepatol. 2026;31:102168

Full text access

Share

Position paper

First Latin American consensus on the treatment and prophylaxis of hepatic encephalopathy

Fátima Higuera-de-la-Tijera, Mario Reis Alvares-da-Silva, Graciela Elia Castro-Narro, Josué Barahona-Garrido, Enrique Carrera-Estupiñán, Jorge Garavito-Rentería, Héctor Adolfo Henríquez-Meléndez, Geovanny Hernández-Cely, ... José Antonio Velarde-Ruiz Velasco

Ann Hepatol. 2026;31:102142

Full text access

Share

Brief report

Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care

Toni Herta, Annegret Franke, Tobias Müller, Kerstin Stein, Heike Bantel, Rainer Günther, Gerald Denk, Philipp A. Reuken, ... Andreas E. Kremer

Ann Hepatol. 2026;31:102140

Full text access

Share

Prospective surveillance reveals high rates of antimicrobial resistance in urinary tract infections among patients with cirrhosis.

Carolina Vazquez, Gonzalo Gómez Perdiguero, Esteban González Ballerga, Ilse Pardo Ivirico, Camila M. Briz, Agustín Di Santo, Maria D. Murga, Ana Palazzo, ... Sebastián Marciano

Ann Hepatol. 2026;31:102135

Full text access

Share

Letters to the editor

Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trial

Nikolaj Torp, Nick Freemantle, Mads Israelsen, Aleksander Krag, Alastair O’Brien

Ann Hepatol. 2026;31:102137

Full text access

Share

Non-hepatic cancers in alcohol-related liver disease with insights for clinical management

Weiyi Jiang, Qianqian Yin, Mengyi Hu, Tingsu Zhang

Ann Hepatol. 2026;31:102152

Full text access

Share

Toward standardization and translation of stem cell therapy in liver failure

Parth Aphale, Himanshu Shekhar, Shashank Dokania

Ann Hepatol. 2026;31:102164

Full text access

Share

Beyond the epidemiological link: Targeting the gut-liver-kidney axis in hepatorenal disease

Songhe Chen, Ye Chen, Kai Chen

Ann Hepatol. 2026;31:102163

Full text access

Share